Posted by Michael Wonder on 02 Sep 2025
Multiple myeloma drug Darzalex to get expanded coverage from September
29 August 2025 - Starting in September, reimbursement for the multiple myeloma treatment Darzalex (daratumumab) will be expanded, reducing the patient's annual out-of-pocket cost from 83.2 million won ($59,970) to about 4.16 million won, annually.
The Ministry of Health and Welfare deliberated and approved the “Revised List of Reimbursed Drugs and Reimbursement Ceiling Amounts,” which contains these details, at the Health Insurance Policy Deliberation Committee meeting on Thursday.
